Biotech firm Libra Therapeutics is developing treatments for neurodegenerative diseases and aims to start Phase 1 clinical trials in 2025. The San Diego-based virtual company, established in 2020, outsources its R&D to contract research organisations (CROs) and relies heavily on data management platform CDD Vault to enable the comparison of diverse data from its CRO partners. Martin Gill, Libra’s Vice President and Head of Biology, stated the company is aiming to be first and best in its class.
‘Amber alert’ as NHS in Plymouth makes urgent plea for people with certain blood type
The NHS has issued an urgent call for O type blood donors, following increased demand after the recent cyber attack. The attack led to reduced
